A meta-analysis of over 9,500 patients in major prostate cancer trials, including the pivotal VISION and PSMA-4 trials for radioligand therapy, shows significant underrepresentation of Black and Hispanic patients. This creates a critical evidence gap when applying these therapies to diverse real-world populations.

Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

Novo Nordisk ran a nearly 4,000-patient Phase 3 Alzheimer's trial despite publicly stating it had a low probability of success. This strategy consumes valuable patient resources, raising ethical questions about whether a smaller, definitive Phase 2 study would have been a more responsible approach for the broader research ecosystem.

With three-quarters of mental health providers being women, the field may have a significant blind spot regarding male issues. This gender imbalance can make it difficult for men to feel seen and heard, creating a structural barrier to effective treatment that goes beyond social stigma and pushes them towards toxic online communities.

The "Matilda Effect" describes how women's scientific contributions are systematically overlooked or misattributed to men. Physicists like Marietta Blau and Biba Chowdhury made Nobel-worthy particle discoveries, but the prizes were awarded to men who replicated their work years later.

While the APOE4 gene is a known risk factor for Alzheimer's, its impact is sexually dimorphic. A female with two copies of the gene has a 15-fold increased risk, whereas a male with two copies has a 10-fold risk. This highlights the unique genetic vulnerability women face.

During the pandemic, numerous researchers admitted to withholding promising ideas. They feared professional backlash, being dismissed by supervisors, or being discredited due to their gender. This highlights how cultural issues in science can stifle innovation even during a global crisis when new ideas are most needed.

The decline in estrogen during perimenopause leads to a significant 30% drop in the brain's ability to use glucose for energy. This metabolic crisis can cause brain fog and may be a key reason why women are disproportionately affected by Alzheimer's disease.

The Phase III DEFI trial for nirogacestat uncovered ovarian toxicity, a previously unexpected side effect. This discovery was a direct result of enrolling a patient population that accurately reflected the disease's high prevalence in young women of childbearing potential.